• 1
    Antithrombotic Trialists, Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 7186.
  • 2
    Second International Study of Infarct Survival (ISIS-2) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 34960.
  • 3
    Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 14215.
  • 4
    Tran H, Anand SS, Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292: 186774.
  • 5
    Evangelista V, Totani L, Rotondo S, Lorenzet R, Tognoni G, De Berardis G, Nicolucci A. Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin? Thromb Haemost 2005; 93: 816.
  • 6
    De Gaetano G, Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001; 357: 8995.
  • 7
    Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001; 85: 26571.
  • 8
    Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, Fitzgerald D, Hirsh J, Husted S, Kvasnicka J, Montalescot G, Garcia Rodriguez LA, Verheugt F, Vermylen J, Wallentin L. (Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology). Eur Heart J 2004; 25: 16681.
  • 9
    Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001; 104: 15779.
  • 10
    Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111: 91321.
  • 11
    Hennekens CH, Schror K, Weisman S, FitzGerald GA. Terms and conditions: semantic complexity and aspirin resistance. Circulation 2004; 110: 17068.
  • 12
    De Gaetano G, Cerletti C. Aspirin resistance: a revival of platelet aggregation tests? J Thromb Haemost 2003; 1: 204850.
  • 13
    Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 17103.
  • 14
    Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110: e48993.
  • 15
    Schafer AI. Genetic and acquired determinants of individual variability of response to antiplatelet drugs. Circulation 2003; 108: 9101.
  • 16
    Quick AJ. Salicylates and bleeding: the aspirin tolerance test. Am J Med Sci 1966; 252: 2659.
  • 17
    De Gaetano G. Historical overview of the role of platelets in hemostasis and thrombosis. Haematologica 2001; 86: 34956.
  • 18
    Szczeklik A, Undas A, Sanak M, Frolow M, Wegrzyn W. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000; 110: 9657.
  • 19
    Gewirtz AS, Miller ML, Keys TF. The clinical usefulness of the preoperative bleeding time. Arch Pathol Lab Med 1996; 120: 3536.
  • 20
    Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shattil SJ, Randolph A, Jakubowski JA, Jennings LK, Scarborough RM. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997; 96: 148894.
  • 21
    Bretschneider E, Glusa E, Schror K. ADP-, PAF- and adrenaline-induced platelet aggregation and thromboxane formation are not affected by a thromboxane receptor antagonist at physiological external Ca++ concentrations. Thromb Res 1994; 75: 23342.
  • 22
    Paul BZ, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A2-induced platelet aggregation. Essential role for p2tac and α2a receptors. J Biol Chem 1999; 274: 2910814.
  • 23
    Cattaneo M. Are bleeding time and PFA-100 useful in the initial screening of patients with mucocutaneous bleedings of hereditary nature? J Thromb Haemost 2004; 2: 8901.
  • 24
    Chakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama MM, Hatmi M, Elalamy I. In vitro aspirin resistance detected by PFA-100TM closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124: 805.
  • 25
    Malinin A, Sperling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004; 15: 295301.
  • 26
    Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 11226.
  • 27
    Ho WK, Hankey GJ, Eikelboom JW. Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure? Blood Coagul Fibrinolysis 2004; 15: 12930.
  • 28
    Cattaneo M. Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 19807.
  • 29
    Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castruzzi G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 31727.
  • 30
    Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 8405.
  • 31
    Capone ML, Taconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004; 109: 146871.
  • 32
    Kearney D, Byrne A, Crean P, Cox D, Fitzgerald DJ. Optimal suppression of thromboxane A2 formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol 2004; 43: 52631.
  • 33
    Pouliot M, Gilbert C, Borgeat P, Poubelle PE, Bourgoin S, Creminon C, Maclouf J, McColl SR, Naccache PH. Expression and activity of prostaglandin endoperoxide synthase-2 in agonist-activated human neutrophils. FASEB J 1998; 12: 110923.
  • 34
    Rocca B, Seccheiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002; 99: 76349.
  • 35
    Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, Sanchez E, Broekman MJ, Marcus AJ. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an atithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97: 3505.
  • 36
    Karim S, Habib A, Levy-Toledano S, Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996; 271: 120428.
  • 37
    Gum PA, Kottke-Marchant K, Poggio ED. Profile and prevalence of aspirin resistance with cardiovascular disease. Am J Cardiol 2001; 88: 2305.
  • 38
    Howard PA. Aspirin resistance. Ann Pharmacother 2002; 36: 16204.
  • 39
    Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 9615.
  • 40
    McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88: 7115.
  • 41
    Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108: 3742.
  • 42
    Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 636.
  • 43
    Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 23316.
  • 44
    Sane DC, McKee SA, Malinin AI, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 2002; 90: 8935.
  • 45
    Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995; 11: 2217.
  • 46
    Zimmermann N, Kienzle P, Weber AA, Gams E, Schror K, Hohlfeld T. Aspirin resistance after coronary graft bypass grafting. J Thorac Cardiovasc Surg 2001; 121: 9824.
  • 47
    Smout J, Stansby G. Aspirin resistance. Br J Surg 2002; 89: 45.
  • 48
    Eikelboom JW, Hirsh J, Weitz J. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 16505.
  • 49
    Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97120.
  • 50
    Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. Aspirin triggers anti-inflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A 2004; 101: 1517883.
  • 51
    Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 180917.
  • 52
    FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 2003; 361: 5424.
  • 53
    Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104: 266672.
  • 54
    Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase: 1. Effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 12230.
  • 55
    Chadrasekharan NV, Hu D, Lamar Turepu Roos K, Evanson EK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-variant inhibited by acetaminophen and other analgesic/antipyretic drugs: clonic, structure, and expression. Proc Natl Acad Sci U S A 2002; 99: 1392631.
  • 56
    Warner TD, Mitchell JA. Cyxlooxygenase-3 (COX-3): filling the gaps toward a COX continuum? Proc Natl Acad Sci U S A 2002; 99: 133713.
  • 57
    Simmons DL, Botting RM, Robertson PM, Madsen ML, Vane JR. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid anti-inflammatory drugs. Proc Natl Acad Sci U S A 1999; 96: 327580.
  • 58
    Zimmermannn N, Wenk A, Kim U, Kienzle P, Weber A-A, Gams E, Schroer K, Hohlfeld T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 5427.
  • 59
    Censarek P, Freidel K, Udelhoven M, Ku S-J, Hohlfeld T, Meyer-Kirchrath J, Schroer K, Weber A-A. Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thromb Haemost 2004; 92: 9258.
  • 60
    Weber A-A, Przytulski B, Schumacher M, Zimmermann N, Emmeran G, Hohlfeld T, Schroer K. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br J Haematol 2002; 117: 4246.
  • 61
    Szczeklik A, Musial J, Undas A, Swadźba J, Góra PF, Piwowarska W, Duplaga M. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16: 94854.
  • 62
    Szczeklik A, Musial J, Undas A, Gajewski P, Góra P, Swadźba J, Jankowski M. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33: 128693.
  • 63
    Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. New Engl J Med 1989; 321: 12935.
  • 64
    Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomized controlled trial. BMJ 2000; 321: 137.
  • 65
    Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 224853.
  • 66
    Szczeklik A, Dropinski J, Radwan J, Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscler Thromb 1992; 12: 54853.
  • 67
    Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 618.
  • 68
    Undas A, Sydor WJ, Brummel K, Musiał J, Mann KG, Szczeklik A. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 2003; 107: 1720.
  • 69
    Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ 2004; 328: 4779.
  • 70
    Christiaens L, Macchi L, Herpin D, Coisne D, Duplantier C, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res 2002; 108: 1159.
  • 71
    Kawasaki T, Ozeki Y, Igawa T, Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000; 31: 5915.
  • 72
    Kunicki TJ. The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol 2002; 22: 1420.
  • 73
    Mustonen P, van Willigen G, Lassila R. Epinephrine – via activation of p38-MAPK – abolishes the effect of aspirin on platelet deposition to collagen. Thromb Res 2001; 104: 43949.
  • 74
    Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 24326.
  • 75
    Szczeklik A, Musial J, Undas A, Sanak M, Dropinski J, Tuleja E, Wegrzyn W. Aspirin and thrombinogenesis. Thromb Res 2003; 110: 3457.
  • 76
    Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, Davi G, Cuccurullo F, Patrono C. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102: 100713.